Navigation Links
Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to 'Keep Enjoying Life's Simple Pleasures'
Date:9/13/2010

 

"Takeda is committed to increasing understanding of gout and fostering meaningful dialogue about the disease," says Robert Spanheimer, M.D., vice president of medical and scientific affairs at Takeda. "We are pleased to partner with the Arthritis Foundation to provide tools and resources needed to increase gout education and enhance communication around gout management."

About Gout

Gout is a chronic, metabolic disease affecting approximately 6 million Americans and is the most common form of inflammatory arthritis in men. The underlying cause of gout is hyperuricemia, a condition characterized by elevated levels of uric acid in the blood.  

A gout attack, or "flare," occurs when excess uric acid in the body begins to form crystals, triggering an inflammatory response in the joints or soft tissue causing extreme discomfort. While gout can affect several different joints, including elbows, knees and wrists, patients most commonly experience attacks in the big toe. The pain of a gout attack may interfere with everyday activities, including work and family events.

In addition to recommended diet and lifestyle changes, experts recognize that achieving and maintaining a healthy uric acid level in the body of less than 6.0 mg/dL can help reduce the risk of future attacks.

About the Arthritis Foundation

The mission of the Arthritis Foundation is to improve lives through leadership in the prevention, control and cure of arthritis and related diseases.  

The Arthritis Foundation is the leading health organization addressing the needs of some 46 million Americans living with doctor-diagnosed arthritis, the nation's most common cause of disability.

The Arthritis Foundation pursues its mission through a focus on:

  • Research: The Arthritis Foundation is the largest nonprofit contributor to arthritis research in the world, advancing
    '/>"/>

SOURCE The Arthritis Foundation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
2. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
3. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
4. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
5. Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee
6. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
7. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
8. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
9. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
10. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Israel , June 19, 2013 ... phase I study in volunteers, and preliminary results from ... ND0612, were presented at the 2013 International Congress of ... levodopa/carbidopa liquid drug formula under development for continuous administration ... constant levodopa plasma concentrations. ND0612 has been ...
(Date:6/19/2013)... 2013  Omnicell, Inc. (NASDAQ: OMCL ... management solutions and analytics software for healthcare facilities, ... one overall pharmacy equipment vendor in the KLAS ... leading independent healthcare research firm, compared the performance ... annual rankings. Omnicell also received the prestigious "Best ...
(Date:6/18/2013)... 19, 2013 , Safinamide ... (PD) patients as add-on to levodopa ... motor symptoms in fluctuating PD patients as add-on ... Pharmaceuticals S.p.A. ("Newron"), a research and development company ... its partner Zambon S.p.A., a pharmaceutical company strongly ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 2Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 3Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6
... how microbes can block nitric,oxide production - a chemical ... fighting bacteria, MEMPHIS, Tenn., Nov. 3 St. ... which,intracellular pathogens can shut down one of the body,s ... that the microbes,block nitric oxide production by subverting the ...
... presented at the 2008 iSBTc Annual Meeting -, ... a.m. ET to discuss,results -, BRANFORD, Conn., Nov. ... preliminary data from an ongoing Phase II,trial of CR011-vcMMAE, ... patients with unresectable Stage III or Stage IV melanoma.,Dr. ...
Cached Medicine Technology:Parasites That Live Inside Cells Use Loophole to Thwart Immune System 2Parasites That Live Inside Cells Use Loophole to Thwart Immune System 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7
(Date:6/19/2013)... that the incidence of cancer is many fold higher ... have an inadequate understanding on how best to treat ... are occasionally included in clinical trials, those elderly patients ... patients. Thus, the broader elderly patient population is not ... the Elderly Task Force is now starting a new ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 The Cancer ... the promise of cancer care for the whole patient ... at the Cancer Support Community. This inaugural event, held ... Ezekiel Emanuel, MD., Ph.D., recognition of Congress members who ... the voices of patients and families currently engaged in ...
(Date:6/19/2013)... Arem Wellness was developed and is ... Dr. Ridha Arem, who is determined to help educate ... goal, Arem Wellness provides a monthly newsletter, a blog, ... as well as an exceptional supplement line uniquely designed ... crucial role diet and nutrition have not only on ...
(Date:6/19/2013)... June 19, 2013 A blow to the ... follows immediately or within minutes to hours. It’s understandable, ... is classified as a mild traumatic brain injury. According ... are headache, amnesia and confusion. But many other symptoms ... initial injury. These may include ongoing headaches, dizziness, feeling ...
(Date:6/19/2013)... Pass, OR (PRWEB) June 19, 2013 To survive ... Navy Pilot and Vietnam veteran Captain W.S. “Bud” Orr, the most ... water. Speaking to host Sharon Kleyne on the Sharon Kleyne Hour ... survival kit in Vietnam, he always placed extra water ahead of ... a weight limit on survival kits that pilots could carry on ...
Breaking Medicine News(10 mins):Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 3Health News:Arem Wellness Announces a Recipe Contest 2Health News:Arem Wellness Announces a Recipe Contest 3Health News:Concussions Can Lead to Much More Than a Headache, According to MMTR Health Inc. Founder, Terry Moore, Neuromuscular and Cardiovascular Physiologist 2Health News:Vietnam Navy Pilot Reveals to Radio Host Sharon Kleyne That He Carried Extra Water Not a Gun in Survival Kit 2
... HealthDay Reporter , WEDNESDAY, Feb. 23 (HealthDay News) -- ... young people who are exposed to violent video games may ... study suggests that may not be the case. Canadian ... run, gamers were just as likely to recall negative images ...
... Amanda Gardner HealthDay Reporter , TUESDAY, Feb. 22 ... areas of your brain closest to the phone,s antenna, but ... pose any long-term health risk. "We don,t know whether ... beneficial effects. We don,t know one way or the other," ...
... one tumor-suppressing protein, Cheryl Walker,s research team at The ... a separate surprise. They found another protective protein known ... the cell,s cytoplasm. Following up on this unexpected ... a second job controlling and killing damaged cells in ...
... population is currently infected by hepatitis C. The virus hides ... and it,s the most frequent cause of liver transplants in ... vaccine, but researchers at the University of Copenhagen are now ... future hope for medical protection from this type of hepatitis. ...
... speed implementation of an electronic health record system in ... major strategic direction of health care reform and must ... to administrators, states a study published in CMAJ ... only) http://www.cmaj.ca/embargo/cmaj100856.pdf . Canada Health Infoway has ...
... , TUESDAY, Feb. 22 (HealthDay News) -- People with chronic ... to develop shingles, according to a new study. Shingles ... a painful rash with lesions. Though it was already ... increased risk for the condition, the researchers of the current ...
Cached Medicine News:Health News:Violent Video Games May Not Desensitize Kids: Study 2Health News:Violent Video Games May Not Desensitize Kids: Study 3Health News:Violent Video Games May Not Desensitize Kids: Study 4Health News:Cell Phones Affect Areas of the Brain, Study Shows 2Health News:Cell Phones Affect Areas of the Brain, Study Shows 3Health News:UT MD Anderson discovery wins 2010 Cozzarelli Prize 2Health News:New vaccine technology protects mice from hepatitis C virus 2Health News:New vaccine technology protects mice from hepatitis C virus 3Health News:New vaccine technology protects mice from hepatitis C virus 4Health News:E-health must align with health care reform 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: